Table 3.
Predictor | PIs vs Other ART Regimens | Atazanavir-Containing, Non–Atazanavir-Containing PI vs Other ART Regimens | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Unadjusted Model (n = 5732) | Time Adjusted Model (n = 5663) | Covariate Adjusted Model (n = 5663) | Time Adjusted Model (n = 5663) | Covariate Adjusted Model (n = 5663) | ||||||
OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | |
ART regimen | ||||||||||
PI + NRTIs | 3.7 (2.4–5.8) | <.01 | 3.9 (2.5–6.2) | <.01 | 3.1 (1.9–5.1) | <.01 | … | … | … | … |
Other ART | 1.0 (Ref.) | … | 1.0 (Ref.) | … | 1.0 (Ref.) | … | … | … | … | … |
ART regimen | ||||||||||
Atazanavir-containing | ... | ... | ... | ... | ... | ... | 3.9 (2.4–6.3) | <.01 | 3.1 (1.9–5.3) | <.001 |
Non-atazanavir-containing PI | ... | ... | ... | ... | ... | ... | 3.4 (2.1–5.6) | <.01 | 2.7 (1.6–4.5) | <.01 |
Other ART | ... | ... | ... | ... | ... | ... | 1.0 (Ref.) | ... | 1.0 (Ref.) | ... |
Estimated years of human immunodeficiency virus infectiona | ... | ... | 1.5 (1.3–1.7) | <.01 | 1.7 (1.4–2.0) | <.01 | 1.5 (1.3–1.7) | <.01 | 1.7 (1.4–2.0) | <.01 |
Nadir CD4+ T-cell countb | ... | ... | ... | ... | 1.2 (1.0–1.5) | .03 | ... | ... | 1.3 (1.0–1.6) | .02 |
Age at study visitc | ... | ... | ... | ... | 0.9 (0.9–1.0) | <.01 | ... | ... | 0.9 (0.9–1.0) | <.01 |
Plasma viral load | ||||||||||
Nonsuppressed (>50 copies/mL) | ... | ... | ... | ... | 1.7 (1.2–2.6) | .01 | ... | ... | 1.7 (1.2–2.6) | <.01 |
Suppressed (≤50 copies/mL) | ... | ... | ... | ... | 1.0 (Ref.) | ... | ... | ... | 1.0 (Ref.) | ... |
Number of lumbar punctures | ... | ... | ... | ... | 1.0 (1.0-1.0) | .77 | ... | ... | 1.0 (1.0-1.0) | .67 |
Cohort indicator | ||||||||||
National NeuroAIDS Tissue Consortium | ... | ... | ... | ... | 1.7 (1.1–2.7) | .02 | ... | ... | 1.7 (1.1–2.7) | .02 |
CHARTER-HIV Neurobehavioral Research Center | ... | ... | ... | ... | 1.0 (Ref.) | ... | ... | ... | 1.0 (Ref.) | ... |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease inhibitor; Ref., reference.
aOR per 5 years of estimated years of human immunodeficiency virus infection.
bOR per 100 cell decrement in nadir CD4+ T-cell count.
cOR per year. For mixed models, all values must be present to be modeled. Models were fit using Proc GLIMMIX for logistic regression for repeated measures with cerebrospinal fluid escape as the dependent variable and predictors as fixed effects. Adjusted models were analyzed with random intercept and time.